Compositions and methods for detecting microorganisms

US10093933B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10093933-B2
Application numberUS-201515112739-A
CountryUS
Kind codeB2
Filing dateFeb 14, 2015
Priority dateFeb 18, 2014
Publication dateOct 9, 2018
Grant dateOct 9, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Described herein are compositions and methods for detecting the presence or absence of a microorganism in a sample comprising contacting the sample with an aptamer capable of binding to a cell-surface protein of the microorganism to form a complex, contacting the mixture with a second aptamer capable of binding to the first cell-surface protein or a second cell-surface protein of the microorganism; and performing an assay to detect the second aptamer, wherein detecting the second aptamer indicates that the microorganism is present in the sample, and wherein not detecting the second aptamer indicates that the microorganism is absent from the sample.

First claim

Opening claim text (preview).

The invention claimed is: 1. A nucleic acid molecule comprising the sequence of GGCWWCGGGWACCWAWWAWNGGWWWAGCC(N) n GWC (SEQ ID NO:14), wherein W is independently, for each occurrence, a C-5 modified pyrimidine, N is any unmodified or modified nucleotide, and n is 0, 1, 2, 3, 4 or 5, wherein the nucleic acid molecule is from about 32 to about 100 nucleotides in length. 2. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule is at least about 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 nucleotides in length. 3. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule comprises a nucleic acid molecule having a sequence selected from the group consisting of SEQ ID NOs:1-8, wherein W is a C-5 modified pyrimidine. 4. The nucleic acid molecule of claim 1 , wherein the C-5 modified pyrimidine is selected from the group consisting of 5-(N-benzylcarboxyamide)-2′-deoxycytidine (BndC); 5-(N-2-phenylethylcarboxyamide)-2′-deoxycytidine (PEdC); 5-(N-3-phenylpropylcarboxyamide)-2′-deoxycytidine (PPdC); 5-(N-1-naphthylmethylcarboxyamide)-2′-deoxycytidine (NapdC); 5-(N-2-naphthylmethylcarboxyamide)-2′-deoxycytidine (2NapdC); 5-(N-1-naphthyl-2-ethylcarboxyamide)-2′-deoxycytidine (NEdC); 5-(N-2-naphthyl-2-ethylcarboxyamide)-2′-deoxycytidine (2NEdC); 5-(N-benzylcarboxyamide)-2′-deoxyuridine (BndU); 5-(N-isobutylcarboxyamide)-2′-deoxyuridine (iBudU); 5-(N-tryptaminocarboxyamide)-2′-deoxyuridine (TrpdU); 5-(N-[1-(3-trimethylammonium)propyl]carboxyamide)-2′-deoxyuridine chloride and 5-(N-naphthylmethylcarboxyamide)-2′-deoxyuridine (NapdU). 5. The nucleic acid molecule of claim 1 , wherein C-5 modified pyrimidine is a 5-(N-naphthylmethylcarboxyamide)-2′-deoxyuridine (NapdU). 6. The nucleic acid molecule of claim 3 , wherein the C-5 modified pyrimidine is selected from the group consisting of 5-(N-benzylcarboxyamide)-2′-deoxycytidine (BndC); 5-(N-2-phenylethylcarboxyamide)-2′-deoxycytidine (PEdC); 5-(N-3-phenylpropylcarboxyamide)-2′-deoxycytidine (PPdC); 5-(N-1-naphthylmethylcarboxyamide)-2′-deoxycytidine (NapdC); 5-(N-2-naphthylmethylcarboxyamide)-2′-deoxycytidine (2NapdC); 5-(N-1-naphthyl-2-ethylcarboxyamide)-2′-deoxycytidine (NEdC); 5-(N-2-naphthyl-2-ethylcarboxyamide)-2′-deoxycytidine (2NEdC); 5-(N-benzylcarboxyamide)-2′-deoxyuridine (BndU); 5-(N-isobutylcarboxyamide)-2′-deoxyuridine (iBudU); 5-(N-tryptaminocarboxyamide)-2′-deoxyuridine (TrpdU); 5-(N-[1-(3-trimethylammonium)propyl]carboxyamide)-2′-deoxyuridine chloride and 5-(N-naphthylmethylcarboxyamide)-2′-deoxyuridine (NapdU). 7. The nucleic acid molecule of claim 3 , wherein C-5 modified pyrimidine is a 5-(N-naphthylmethylcarboxyamide)-2′-deoxyuridine (NapdU).

Assignees

Inventors

Classifications

  • from Staphylococcus (G) · CPC title

  • Aptamers · CPC title

  • SELEX · CPC title

  • for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites · CPC title

  • for microorganisms, e.g. protozoa, bacteria, viruses · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10093933B2 cover?
Described herein are compositions and methods for detecting the presence or absence of a microorganism in a sample comprising contacting the sample with an aptamer capable of binding to a cell-surface protein of the microorganism to form a complex, contacting the mixture with a second aptamer capable of binding to the first cell-surface protein or a second cell-surface protein of the microorgan…
Who is the assignee on this patent?
Somalogic Inc
What technology area does this patent fall under?
Primary CPC classification G01N33/5308. Mapped technology areas include Physics.
When was this patent published?
Publication date Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).